Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn's disease

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1786-1793

  Lee, Dale ^a,b,c   Baldassano, Robert N ^a   Otley, Anthony R ^d   Albenberg, Lindsey ^a   Griffiths, Anne M ^e   Compher, Charlene ^f   Chen, Eric Z ^g   Li, Hongzhe ^g   Gilroy, Erin ^g   Nessel, Lisa ^g   Grant, Amy ^d   Chehoud, Christel ^g   Bushman, Frederic D ^g   Wu, Gary D ^h   Lewis, James D ^g,h  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d IWK HEALTH CENTRE   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF PENNSYLVANIA SCHOOL OF NURSING   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anti TNF; Enteral nutrition; Mucosal healing; Pediatric Crohn's disease

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; BODY IMAGE; CHILD; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DIET THERAPY; DISEASE DURATION; DRUG EXPOSURE; ENTERIC FEEDING; EXCLUSIVE ENTERAL NUTRITION; FECES LEVEL; FEMALE; FOOD INTAKE; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL ENTERAL NUTRITION; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; REMISSION; SOCIAL INTERACTION; SYMPTOM; TREATMENT DURATION; COMPARATIVE STUDY; FEEDING BEHAVIOR; FOLLOW UP; PROGNOSIS;

ADOLESCENT; BIOLOGICAL THERAPY; CHILD; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; FOLLOW-UP STUDIES; FOOD HABITS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944237808     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000426     Document Type: Article

References (31)

1. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468; quiz e10-e11.
2. Ruemmele FM, Hyams JS, Otley A, et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut. 2014;3:438-446.
3. De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2013;19:429-444.
4. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;10:1179-1207.
5. Day AS, Whitten KE, Sidler M, et al. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther. 2008;27:293-307.
6. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-753.
7. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-1166.
8. Werkstetter KJ, Schatz SB, Alberer M, et al. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn's disease patients. Ann Nutr Metab. 2013;63:10-16.
9. Whitten KE, Leach ST, Bohane TD, et al. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol. 2010;45:399-405.
10. Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut. 2006;55:356-361.
11. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an "half elemental diet" as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333-1340.
12. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007;1:CD000542.
13. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826 e2.
14. Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841-845.
15. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
16. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
17. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
18. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:15-19, 1-211.
19. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407-1415.
20. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35:557-563.
21. Otley AR, Griffiths AM, Hale S, et al. Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:684-691.
22. Institute of Medicine FaNB. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press; 2002.
23. Cadarette SM, Gagne JJ, Solomon DH, et al. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf. 2010;19:2-9.
24. Lindor KD, Fleming CR, Burnes JU, et al. A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc. 1992;67:328-333.
25. Malchow H, Steinhardt HJ, Lorenz-Meyer H, et al. Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol. 1990;25:235-244.
26. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167-172.
27. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis. 2014;20:1353-1360.
28. Uritski R, Barshack I, Bilkis I, et al. Dietary iron affects inflammatory status in a rat model of colitis. J Nutr. 2004;134:2251-2255.
29. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
30. Fave G, Beckmann ME, Draper JH, et al. Measurement of dietary exposure: a challenging problem which may be overcome thanks to metabolomics? Genes Nutr. 2009;4:135-141.
31. Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.